See more : UMC, Inc. (UMCN) Income Statement Analysis – Financial Results
Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Bank of America Corporation PFD SER B 7% (BACRP) Income Statement Analysis – Financial Results
- Mangal Credit and Fincorp Limited (MANCREDIT.BO) Income Statement Analysis – Financial Results
- ProSight Global, Inc. (PROS) Income Statement Analysis – Financial Results
- Home Control International Limited (1747.HK) Income Statement Analysis – Financial Results
- Elgi Rubber Company Limited (ELGIRUBCO.NS) Income Statement Analysis – Financial Results
Aclaris Therapeutics, Inc. (ACRS)
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.25M | 29.75M | 6.76M | 6.48M | 4.23M | 10.09M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 18.08M | 11.96M | 4.71M | 5.13M | 4.06M | 6.85M | 1.21M | 120.00K | 90.00K | 0.00 | 0.00 |
| Gross Profit | 13.17M | 17.79M | 2.05M | 1.35M | 172.00K | 3.24M | 476.00K | -120.00K | -90.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 42.14% | 59.80% | 30.29% | 20.81% | 4.07% | 32.12% | 28.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.38M | 77.81M | 43.81M | 31.73M | 64.90M | 63.01M | 39.79M | 33.48M | 15.34M | 6.51M | 3.49M |
| General & Administrative | 31.10M | 25.13M | 23.62M | 20.53M | 27.16M | 27.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 283.00K | 671.00K | 48.00M | 85.00K | 3.30M | 0.00 | 0.00 | 0.00 |
| SG&A | 31.10M | 25.13M | 23.62M | 20.53M | 27.83M | 75.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Other Expenses | 0.00 | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | 2.07M | 488.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 130.80M | 102.95M | 67.43M | 52.26M | 92.73M | 138.66M | 72.90M | 48.57M | 20.67M | 8.53M | 5.26M |
| Cost & Expenses | 128.61M | 114.91M | 72.15M | 57.39M | 96.78M | 145.51M | 74.11M | 48.57M | 20.67M | 8.53M | 5.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.00K | 16.00K | 21.00K |
| Interest Expense | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 863.00K | 797.00K | 923.00K | 1.32M | 1.59M | 1.32M | 402.00K | 120.00K | 90.00K | 12.00K | 11.00K |
| EBITDA | -117.57M | -84.36M | -65.06M | -48.20M | -90.84M | -80.78M | -53.45M | -48.57M | -20.67M | -8.52M | -5.25M |
| EBITDA Ratio | -376.22% | -267.74% | -607.08% | -785.44% | -1,751.83% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -97.36M | -85.15M | -65.38M | -50.91M | -111.06M | -135.41M | -72.42M | -48.57M | -20.67M | -8.53M | -5.26M |
| Operating Income Ratio | -311.55% | -286.21% | -967.08% | -785.44% | -2,627.35% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.51M | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | -15.99M | 488.00K | 104.00K | 16.00K | 21.00K |
| Income Before Tax | -88.85M | -86.91M | -90.87M | -51.34M | -113.54M | -132.74M | -70.35M | -48.08M | -20.56M | -8.52M | -5.24M |
| Income Before Tax Ratio | -284.32% | -292.11% | -1,343.96% | -791.98% | -2,686.11% | -1,315.41% | -4,180.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -367.00K | 1.75M | 23.42M | -182.00K | 29.31M | 2.68M | -1.83M | -120.00K | -90.00K | 0.00 | 0.00 |
| Net Income | -88.48M | -88.66M | -114.28M | -51.15M | -142.85M | -132.74M | -68.52M | -48.08M | -20.56M | -8.52M | -5.24M |
| Net Income Ratio | -283.15% | -298.00% | -1,690.30% | -789.17% | -3,379.47% | -1,315.41% | -4,071.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| EPS Diluted | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| Weighted Avg Shares Out | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
These 2 Biotech Stocks Made Big Monday Moves
Why Aclaris Therapeutics Is Crashing Today
Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
Source: https://incomestatements.info
Category: Stock Reports